Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease

Pharmacological Research

Volumn 65, Issue 5, 2012, Pages 514-522

  Laloux, C ^a   Petrault, M ^a   Lecointe, C ^a   Devos, D ^a   Bordet, R ^a  

^a UNIV LILLE   (France)

Author keywords

6 OHDA; MPTP; Parkinson's disease; Pioglitazone; PPAR

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; OXIDOPAMINE; PIOGLITAZONE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; FOREFOOT; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; MUSCLE STRENGTH; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA PARS COMPACTA; WEIGHT REDUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; MPTP POISONING; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PPAR GAMMA; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; THIAZOLIDINEDIONES; VISUAL CORTEX;

EID: 84859795927     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2012.02.008     Document Type: Article

References (63)

1. Bordet R, Ouk T, Petrault O, Gele P, Gautier S, Laprais M, et al. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 2006;34(Pt 6):1341-6. (Pubitemid 46769051)
2. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002;53:409-35. (Pubitemid 34177889)
3. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999;20(5):649-88. (Pubitemid 30650602)
4. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001;169(3):453-9. (Pubitemid 32536978)
5. Kapadia R, Yi JH, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci 2008;13:1813-26. (Pubitemid 351599735)
6. Kaundal RK, Sharma SS. Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents. Drug News Perspect 2010;23(4):241-56.
7. Sundararajan S, Jiang Q, Heneka M, Landreth G. PPARgamma as a therapeutic target in central nervous system diseases. Neurochem Int 2006;49(2):136-44. (Pubitemid 43867071)
8. Schmidt S, Moric E, Schmidt M, Sastre M, Feinstein DL, Heneka MT. Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients. J Leukoc Biol 2004;75(3):478-85. (Pubitemid 38316379)
9. Shimazu T, Inoue I, Araki N, Asano Y, Sawada M, Furuya D, et al. A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke 2005;36(2):353-9. (Pubitemid 40170822)
10. Zhao Y, Patzer A, Herdegen T, Gohlke P, Culman J. Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J 2006;20(8):1162-75. (Pubitemid 44943912)
11. Collino M, Patel NS, Thiemermann C. PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury. Ther Adv Cardiovasc Dis 2008;2(3):179-97. (Pubitemid 351859071)
12. Fong WH, Tsai HD, Chen YC, Wu JS, Lin TN. Anti-apoptotic actions of PPARgamma against ischemic stroke. Mol Neurobiol 2010;41(2-3):180-6.
13. Landreth G, Jiang Q, Mandrekar S, Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 2008;5(3):481-9. (Pubitemid 351952487)
14. Moraes LA, Piqueras L, Bishop-Bailey D. Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 2006;110(3):371-85.
15. Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002;82(3):615-24. (Pubitemid 34831499)
16. Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 2004;88(2):494-501. (Pubitemid 38084565)
17. Quinn LP, Crook B, Hows ME, Vidgeon-Hart M, Chapman H, Upton N, et al. The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. Br J Pharmacol 2008;154(1):226-33. (Pubitemid 351620404)
18. Swanson CR, Joers V, Bondarenko V, Brunner K, Simmons HA, Ziegler TE, et al. The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation 2011;8:91.
19. Barbiero JK, Santiago RM, Lima MM, Ariza D, Morais LH, Andreatini R, et al. Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease. Behav Brain Res 2011;216(1):186-92.
20. Ulusoy GK, Celik T, Kayir H, Gursoy M, Isik AT, Uzbay TI. Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease. Brain Res Bull 2011.
21. Kreisler A, Duhamel A, Vanbesien-Mailliot C, Destee A, Bordet R. Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease. Behav Pharmacol 2010;21(3):194-205.
22. Cheramy A, Chesselet MF, Romo R, Leviel V, Glowinski J. Effects of unilateral electrical stimulation of various thalamic nuclei on the release of dopamine from dendrites and nerve terminals of neurons of the two nigrostriatal dopaminergic pathways. Neuroscience 1983;8(4):767-80. (Pubitemid 13122681)
23. Sirinathsinghji DJ, Whittington PE, Audsley AR. Neurochemical changes in the substantiae nigrae and caudate nuclei following acute unilateral intranigral infusions of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Brain Res 1986;399(2):339-45. (Pubitemid 17231321)
24. Lawler CP, Gilmore JH, Watts VJ, Walker QD, Southerland SB, Cook LL, et al. Interhemispheric modulation of dopamine receptor interactions in unilateral 6-OHDA rodent model. Synapse 1995;21(4):299-311. (Pubitemid 26039646)
25. Roedter A, Winkler C, Samii M, Walter GF, Brandis A, Nikkhah G. Comparison of unilateral and bilateral intrastriatal 6-hydroxydopamine-induced axon terminal lesions: evidence for interhemispheric functional coupling of the two nigrostriatal pathways. J Comp Neurol 2001;432(2):217-29. (Pubitemid 32187013)
26. Dzahini K, Dentresangle C, Le Cavorsin M, Bertrand A, Detraz I, Savasta M, et al. Pre-synaptic glutamate-induced activation of DA release in the striatum after partial nigral lesion. J Neurochem 2010;113(6):1459-70.
27. Ungerstedt U. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 1971;367:95-122.
28. Cenci MA, Whishaw IQ, Schallert T. Animal models of neurological deficits: how relevant is the rat? Nat Rev Neurosci 2002;3(7):574-9. (Pubitemid 135706667)
29. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. New York: Academic; 1986.
30. Bordet R, Ridray S, Carboni S, Diaz J, Sokoloff P, Schwartz JC. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 1997;94(7):3363-7. (Pubitemid 27157317)
31. Cabe PA, Tilson HA, Mitchell CL, Dennis R. A simple recording grip strength device. Pharmacol Biochem Behav 1978;8(1):101-2. (Pubitemid 8287117)
32. Petroske E, Meredith GE, Callen S, Totterdell S, Lau YS. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 2001;106(3):589-601. (Pubitemid 32925247)
33. Kreisler A, Gele P, Wiart JF, Lhermitte M, Destee A, Bordet R. Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not. Brain Res 2007;1135(1):77-84. (Pubitemid 46176827)
34. Schintu N, Frau L, Ibba M, Caboni P, Garau A, Carboni E, et al. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur J Neurosci 2009;29(5):954-63.
35. Hunter RL, Dragicevic N, Seifert K, Choi DY, Liu M, Kim HC, et al. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem 2007;100(5):1375-86.
36. Hunter RL, Choi DY, Ross SA, Bing G. Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats. Neurosci Lett 2008;432(3):198-201.
37. Yu HC, Feng SF, Chao PL, Lin AM. Anti-inflammatory effects of pioglitazone on iron-induced oxidative injury in the nigrostriatal dopaminergic system. Neuropathol Appl Neurobiol 2010;36(7):612-22.
38. Xing B, Liu M, Bing G. Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-kappaB and JNK activation and suppression of COX-2 activity. J Neuroimmunol 2007;192(1-2):89-98.
39. Jung TW, Lee JY, Shim WS, Kang ES, Kim SK, Ahn CW, et al. Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehydeinduced cytotoxicity. Biochem Biophys Res Commun 2006;340(1): 221-7. (Pubitemid 41827669)
40. Jung TW, Lee JY, Shim WS, Kang ES, Kim SK, Ahn CW, et al. Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production. J Neurol Sci 2007;253(1-2):53-60. (Pubitemid 46185454)
41. Shah P, Mudaliar S. Pioglitazone: side effect and safety profile. Expert Opin Drug Safety 2010;9(2):347-54.
42. Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp Neurol 2004;187(2):455-9. (Pubitemid 38610291)
43. Salonen T, Haapalinna A, Heinonen E, Suhonen J, Hervonen A. Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity. Acta Neuropathol 1996;91(5):466-74. (Pubitemid 26133657)
44. Heneka MT, Klockgether T, Feinstein DL. Peroxisome proliferatoractivated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 2000;20(18): 6862-7.
45. Wada K, Kamisaki Y. Anti-inflammatory effect of PPARgamma agonists: basics and clinical applications. Nihon Rinsho 2010;68(2):278-83.
46. Rizzo G, Fiorucci S. PPARs and other nuclear receptors in inflammation. Curr Opin Pharmacol 2006;6(4):421-7.
47. Chung JH, Seo AY, Chung SW, Kim MK, Leeuwenburgh C, Yu BP, et al. Molecular mechanism of PPAR in the regulation of age-related inflammation. Ageing Res Rev 2008;7(2):126-36.
48. Kumar R, Agarwal AK, Seth PK. Free radical-generated neurotoxicity of 6-hydroxydopamine. J Neurochem 1995;64(4):1703-7.
49. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 2001;65(2):135-72. (Pubitemid 32524182)
50. Bove J, Prou D, Perier C, Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2005;2(3):484-94. (Pubitemid 41444882)
51. Yokoyama H, Kuroiwa H, Yano R, Araki T. Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease. Neurol Sci 2008;29(5):293-301.
52. Schmidt N, Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. J Neural Transm 2001;108(11):1263-82. (Pubitemid 33141302)
53. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391(6662):82-6. (Pubitemid 28079219)
54. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 1994;172(1-2):151-4. (Pubitemid 24178765)
55. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferatoractivated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391(6662):79-82. (Pubitemid 28079218)
56. Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 2000;20(2):558-67. (Pubitemid 30225558)
57. Carta AR, Frau L, Pisanu A, Wardas J, Spiga S, Carboni E. Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model. Neuroscience 2011;194:250-61.
58. Kirik D, Rosenblad C, Björklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 1998;152(2):259-77. (Pubitemid 28419264)
59. Yuan H, Sarre S, Ebinger G, Michotte Y. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. J Neurosci Methods 2005;144(1):35-45. (Pubitemid 40546300)
60. Sauer H, Oertel WH. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994;59(2):401-15. (Pubitemid 24098798)
61. Amalric M, Moukhles H, Nieoullon A, Daszuta A. Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat. Eur J Neurosci 1995;7(5):972-80.
62. Lindner MD, Cain CK, Plone MA, Frydel BR, Blaney TJ, Emerich DF, et al. Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middleaged rats. Behav Brain Res 1999;102(1-2):1-16. (Pubitemid 29314564)
63. Chaturvedi RK, Beal MF. PPAR: a therapeutic target in Parkinson's disease. J Neurochem 2008;106(2):506-18.